Navigation Links
MEM in Medical Technology

Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia

-Triggers $5 Million Payment from Roche- MONTVALE, N.J., Nov. 19 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY ) today announced that it has achieved the enrollment goal for its Phase 2 trial of R3487/MEM 3454, its lead alpha-7 nicotinic receptor agonist, in cogni...

Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals' Nicotinic Alpha-7 Agonist, MEM 3454

-Memory Receives $6 Million Milestone Payment- -Memory to Host Conference Call at 9:00 a.m. EDT Today- MONTVALE, N.J. and BASEL, Switzerland, May 2 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY ) and Roche (SWX: ROG) today announced that Roche has ex...

Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia

- Establishes Plan for Biomarker Study - MONTVALE, N.J., Feb. 19 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY ) today announced that it plans to conduct a clinical study of MEM 3454, the Company's lead nicotinic alpha-7 partial agonist, on two biomarker...

Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease

-Company to Host Conference Call at 9:00 a.m. EDT- MONTVALE, N.J., Oct. 15 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY ) today announced top-line data from the multi-center, randomized, double-blind, placebo-controlled Phase 2a study of MEM 1003, a neuronal...

Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day

...munity. The Company reported new clinical data for mem 1414, its lead PDE4 inhibitor, demonstrating the c... in humans. In addition, the Company has nominated mem 68626 as the lead development candidate from its 5...r, we are pleased to report that we have nominated mem 68626 as the lead compound in our 5-HT6 antagonist...

Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results

...ths, highlighted by our positive Phase 2a data for mem 3454 in Alzheimer's disease, the expansion of our schizophrenia development program for mem 3454 with our partner Roche, and the completion of...4996/MEM 63908, and initiate a biomarker study for mem 3454 in schizophrenia." Financial Results For ...
MEM in Biological Technology

Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia

MONTVALE, N.J., Dec. 20 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY ) today announced dosing of the first subject in a randomized, double-blind, placebo-controlled Phase 2a clinical trial of MEM 3454, the Company's lead nicotinic alpha-7 receptor partial agonist, in c...

Double Helix Strengthens its Strategic Pricing and Reimbursement Practice with Hire of Caryn Zieses

... previous client services experience in the Equity Research division of Lehman Brothers. Caryn holds an MBA from the Kellogg School of Management, an mem from Northwestern University, and a BSE in Chemical Engineering from the University of Pennsylvania. http://www.doublehelixdevelopment.c...

Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results

...E10 inhibitor program and from SMRI related to the mem 1003 program which were recognized in 2007 but not...administrative costs and costs associated with the mem 1003 program. General and administrative expense...ory Pharmaceuticals presented preclinical data for mem 68626, its lead 5-HT6 antagonist, in a poster pres...

Memory Pharmaceuticals Reports First Quarter 2008 Financial Results

...nd our Phase 1 program for R4996/MEM 63908, initiating a Phase 2a trial for mem 1414, and advancing our 5-HT6 antagonist program into the clinic." Financ... $3.4 million decrease in costs associated with the clinical development of mem 1003. General and administrative expenses for the quarter ended March 31,...

Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs

...lpha-7 Receptor Agonist Collaboration with Roche. mem 3454, the lead compound in the Company's ni...y expects to initiate a biomarker study for mem 3454 in schizophrenia this summer, with res...expects to complete its Phase 1 program for mem 63908 and report top-line results in the fourth qu...

Neurobiological Technologies Announces Pricing of Its $60 Million Common Stock Offering

...will receive approximately $55 million of net offering proceeds, after underwriting discounts and estimated costs. Merriman Curhan Ford & Co. (Amex: mem ) acted as the sole book-running manager in this offering, and Dawson James Securities, Inc. acted as co-manager. Copies of the final prospectus may ...

Agendia BV Appoints Clinical and Scientific Advisory Board

...esearch programs and provide critical evaluations from academic and clinical perspectives. Agendia welcomes: Piet Borst (chair), M.D., PhD, CBE, For mem RS, Staff Member and Emeritus Director of the Netherlands Cancer Institute and Professor of Clinical Biochemistry, Amsterdam, The Netherlands Jose Ba...

Bionovo Announces Proposed Public Offering of Common Stock

...al Markets Corp. and Canaccord Adams Inc. are acting as joint book-running managers for the proposed offering, with Merriman Curhan Ford & Co. (Amex: mem ) acting as a co-manager. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sal...

Screening for β2-adrenergic receptor agonists using the pH-sensitive dye,CypHer5, and the IN Cell Analyzer 3000

... LOPAC (Sigma)

Culture medium: mem (Sigma) containing 10% (v/v) FBS, 200 µ g/ml G418, L-glutamine, non-essential amino acids

Assay medium: mem (Sigma)

Agonist: Isoproterenol (Sigma) ...

The use of CypHer5E and the IN Cell Analyzer 1000 for live-cell receptor internalization studies

...EK293 cell line expressing EGF receptor HEK Culture medium: mem (Sigma M2279) containing: 10% (v/v) FBS Geneticin G418...

4. Replace the culture medium with 100 µl/well of fresh mem (phenol red free) containing 2.5–5 µg/ml CypHer5E anti-VSV-G an...

More>>

Other Tags
(Date:9/18/2014)... It’s been just a few short weeks since ... splint to website visitors, but already the response has been ... delighted. It is perfect and I find it sooo much ... YOU FOR LISTENING!!!" Another user compared the original design ... to slip to the end of my toe. Now that ...
(Date:9/18/2014)... LAKE, Wis. (PRWEB) September 18, 2014 It ... and engage in health and wellness. Once again, Evensong ... in Spa Week by offering three services at a special ... Evensong Spa, managed by Marcus Hotels & Resorts , ... a national event encouraging Americans to embrace health and wellness ...
(Date:9/18/2014)... 2014 (HealthDay News) -- Daily supplements of selenium or ... development of age-related cataracts among men, a new study ... or both could help prevent cataracts. To investigate this ... Harvard Medical School in Boston, and his colleagues examined ... vitamin E. The trial was initially designed to study ...
(Date:9/18/2014)... In 2003, the government ... Barrio Adentro), which it hoped would increase ... Section 6.1.3.). In 2009, it invested VEF28 ... of Pharmaceutical Elaborations (Servicio Autónomo de Elaboraciones ... at a cheaper rate than private pharmaceutical ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Qualis Health, ... has published a white paper, “Advancing Primary Care ... Health Information Technology.” , Authors Jeff Hummel, MD, ... provide guidance to organizations engaged in the work of ... health IT can bolster PCMH objectives, such as generating ...
Breaking Medicine News(10 mins):Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 2Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 3Health News:Evensong Spa Celebrates Spa Week with $50 Services 2Health News:Evensong Spa Celebrates Spa Week with $50 Services 3Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 3Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 4Health News:Advancing Primary Care Through PCMH and HIT: New White Paper Connects the Dots 2
(Date:9/18/2014)... carbon and nitrogen comprise all spheres of our ... have caused imbalances and perturbations that resulted in ... GHGs result in climate changes which influence the ... the atmosphere. Understanding these feedback mechanisms has become ... science during the past three decades. , In ...
(Date:9/18/2014)... to 400 kilometres in search of a home, which makes ... spend their entire adult lives under the protection of their ... ocean, says study co-author, Dr Hugo Harrison from the ARC ... James Cook University. , "In the past we haven,t known ... glimpse into how far they can swim, crossing large tracts ...
(Date:9/17/2014)... his doctoral student have designed a device based on ... fog and dew., The device could provide water in ... globe., Cheng Luo, professor in the Mechanical & Aerospace ... same College of Engineering department, published "Bioinspired Plate-Based Fog ... Chemical Society) Applied Materials & Interfaces ...
Breaking Biology News(10 mins):Greenhouse gas research enters a new era 2Nemo's epic journey to find a new home 2Shorebird's beak inspires UT Arlington research on water collection 2
Other Contents